ARQ 621

Research use only, not for human use.

ARQ 621 is an allosteric, and selective Eg5 mitotic motor protein inhibitor. Phase 1.

ARQ-621 is an allosteric, potent and selective inhibitor of Eg5, a microtubule-based ATPase motor protein involved in cell division. Over-expression of Eg5 causes genomic instability and tumor formation in mice; therefore, Eg5 is a potential anti-cancer target. Preclinical data shows anti-tumor activity of ARQ 621 across a wide range of cell lines from human solid and hematological malignancies.(In Vitro):Over-expression of Eg5 causes genomic instability and tumor formation in mice; therefore, Eg5 is a potential anti-cancer target.

Over-expression of Eg5 causes genomic instability and tumor formation in mice; therefore, Eg5 is a potential anti-cancer target.

——

ARQ621 | ARQ 621 | ARQ-621

Metabolic Enzyme/Protease

BACE

Eg5 mitotic motor protein

Cancer

——

1095253-39-6

552.43

C28H24Cl2FN5O2

>98% (HPLC)

In Vitro:?DMSO : 110 mg/mL (199.12 mM)

NCCCN([C@H](CC#C)C1=NC2=C(C=CC(Cl)=C2)C(=O)N1NC1=CC=CC=C1)C(=O)C1=CC=CC(Cl)=C1F

(R)-N-(3-aminopropyl)-3-chloro-N-(1-(7-chloro-4-oxo-3-(phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-yn-1-yl)-2-fluorobenzamide

(-20℃)

With Ice Pack

≥ 2 years